Trial: 201904207

NRG GY012: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer

Phase

II

Principal Investigator

Mutch, David

Disease Site

Corpus Uteri

Learn more about this study at: clinicaltrials.gov